Skip to content
TaiRx, Inc. | New Drug Development Logo TaiRx, Inc. | New Drug Development Logo TaiRx, Inc. | New Drug Development Logo
  • About Us
    • Meet TaiRx
    • Vision
    • Innovation
    • Management Team
    • Scientific Advisory Committee
    • Board of Directors
  • Product Pipeline
    • CVM-1118
    • Rexis®
    • TRX-711
    • TRX-NOC
    • TRX-920
    • TRX-105
  • Market Product
  • News
  • Contact Us
  • enEnglish
    • zh-hant繁體中文

TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June.

2017/6/15 TaiRx shows its potential in new cancer drug development and will be listed on the emerging stock market on June 20th. […]

TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June. Chang Lisa 2018-06-04T17:50:50+00:00

TaiRx presents CVM-1118 Phase I Clinical Trial Progress at ASCO

2017/6/5 TaiRx, Inc. (6580) publishes its Phase I clinical trial result in the United States and Taiwan on CVM-1118, a new cancer drug, at [...]

TaiRx presents CVM-1118 Phase I Clinical Trial Progress at ASCO Chang Lisa 2018-06-04T17:50:56+00:00

Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer.

2016/06/17 This issue of Science magazine (June 17, 2016) featured a column on how malignant tumor cells avoid traditional anti-angiogenesis mechanism and achieve metastasis. [...]

Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer. Chang Lisa 2018-06-04T17:51:02+00:00

TaiRx’s oral cancer drug with a promising forecast.

2016/3/28 […]

TaiRx’s oral cancer drug with a promising forecast. Chang Lisa 2021-02-17T15:02:16+00:00

23 major pharmaceutical companies attended the cross-strait new drug discussion panel.

2016/3/18 […]

23 major pharmaceutical companies attended the cross-strait new drug discussion panel. Chang Lisa 2021-02-17T14:59:11+00:00

TaiRx receives Honorable recognition at the 12th Taiwan National Innovation Award.

2015/12/24 […]

TaiRx receives Honorable recognition at the 12th Taiwan National Innovation Award. Chang Lisa 2021-02-17T11:19:32+00:00

TaiRx received Honorable award at the 2015 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award Competition.

2015/9/24 […]

TaiRx received Honorable award at the 2015 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award Competition. Chang Lisa 2021-02-17T13:44:45+00:00

TaiRx received the Bronze Award at the 2015 Taipei Biotech Award Competition.

2015/7/24 Bio@Taipei […]

TaiRx received the Bronze Award at the 2015 Taipei Biotech Award Competition. Chang Lisa 2021-02-17T13:48:45+00:00

CVM-1118 IND approved by the US FDA to initiate Phase I clinical study in US.

2015/5/13 CVM-1118 from TaiRx, Inc. receives US FDA approval to initiate Phase I clinical study. TaiRx’s IND application received its approval in 30 days [...]

CVM-1118 IND approved by the US FDA to initiate Phase I clinical study in US. Chang Lisa 2018-06-04T17:51:46+00:00

TaiRx signed research contract with Northwestern University Ann & Robert H. Lurie Children’s Hospital of Chicago to evaluate Nodal, a novel oncology target

2014/3/14 […]

TaiRx signed research contract with Northwestern University Ann & Robert H. Lurie Children’s Hospital of Chicago to evaluate Nodal, a novel oncology target Chang Lisa 2018-06-04T17:51:53+00:00
Previous123Next
Copyright© 2018 台睿生物科技股份有限公司 | 網頁設計公司:振作國際